The U.S. Food and Drug Administration (FDA) has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent (siponimod), to treat people with relapsing forms of multiple sclerosis (MS). According to a company press release, the therapy is indicated for use in adults with clinically isolated syndrome, relapsing-remitting MS (RRMS), or active secondary progressive MS (SPMS). Similar […]
The post FDA gives tentative approval to generic Siponimod tablets for MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com